Table 1. Baseline characteristics of randomised patients (safety population).
| ASA404-CP (n=37) | CP (n=36) | |
|---|---|---|
| Men, n (%) | 23 (62.2) | 24 (66.7) |
| Women, n (%) | 14 (37.8) | 12 (33.3) |
| Age (years), mean±s.d. | 59.4±8.91 | 61.0±10.76 |
| Histological subtype, n (%) | ||
| Squamous cell carcinoma/undifferentiated | 11 (29.7) | 11 (30.6) |
| Adenocarcinoma | 25 (67.6) | 22 (61.1) |
| Large cell carcinoma | 0 | 2 (5.6) |
| Other | 1 (2.7) | 1 (2.8) |
| Stage, n (%) | ||
| IIIb | 11 (29.7) | 13 (36.1) |
| IV | 26 (70.3) | 23 (63.9) |
| Karnofsky performance status, n (%) | ||
| 70 | 1 (2.7) | 3 (8.3) |
| 80 | 9 (24.3) | 9 (25.0) |
| 90 | 17 (45.9) | 14 (38.9) |
| 100 | 10 (27.0) | 10 (27.8) |
ASA404-CP=ASA404 combined with carboplatin and paclitaxel; CP=carboplatin and paclitaxel; s.d.=standard deviation.